Skip to main content

Table 2 Correlation between 25-point vitreomacular interface score and other studied Parameters

From: Influence of vitreomacular interface score on treatment outcomes of anti-VEGF therapy for neovascular age-related macular degeneration

Clinical parameters

Univariable analysis

Multivariable analysis

P

r

P

β

Age

0.04*

0.27

0.48

0.10

Sex (1, male; 2, female)

0.58

0.07

  

Subtype (1, tAMD; 2, PCV)

0.46

0.10

  

Axial length

0.43

0.11

  

LogMAR BCVA

 Baseline

0.02*

0.30

0.11

0.21

 1-year follow-up

0.04*

0.28

0.24

0.16

Central retinal thickness at baseline

0.51

− 0.09

  

Subfoveal choroidal thickness at baseline

0.01*

− 0.32

0.02*

− 0.31

Genotype

 ARMS2 A69S (0, GG; 1, GT; 2, TT)

0.06a

0.25

0.51

0.09

 CFH I62V (0, AA; 1, AG; 2, GG)

0.06b

− 0.25

0.20

− 0.17

  1. Data are presented as means ± standard deviations where applicable
  2. tAMD, typical age-related macular degeneration; PCV, polypoidal choroidal vasculopathy; logMAR BCVA, logarithm of the minimal angle of resolution best-corrected visual acuity; ARMS2, age-related maculopathy susceptibility protein 2; CFH, complement factor H
  3. In measurements indicated by a and b, data are missing for two and two patients, respectively
  4. *Statistically significant (P < 0.05)